Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Interest Expenses (2023 - 2025)

Historic Interest Expenses for Harmony Biosciences Holdings (HRMY) over the last 3 years, with Q3 2025 value amounting to $3.6 million.

  • Harmony Biosciences Holdings' Interest Expenses fell 1672.03% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 1532.38%. This contributed to the annual value of $17.5 million for FY2024, which is 2635.43% down from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Interest Expenses stood at $3.6 million, which was down 1672.03% from $3.6 million recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Interest Expenses peaked at $7.0 million during Q3 2023, and registered a low of $3.6 million during Q3 2025.
  • Over the past 3 years, Harmony Biosciences Holdings' median Interest Expenses value was $4.4 million (recorded in 2024), while the average stood at $4.8 million.
  • Over the last 5 years, Harmony Biosciences Holdings' Interest Expenses had its largest YoY gain of 1223.94% in 2024, and its largest YoY loss of 3799.2% in 2024.
  • Quarter analysis of 3 years shows Harmony Biosciences Holdings' Interest Expenses stood at $4.8 million in 2023, then fell by 12.24% to $4.2 million in 2024, then decreased by 13.97% to $3.6 million in 2025.
  • Its Interest Expenses was $3.6 million in Q3 2025, compared to $3.6 million in Q2 2025 and $3.8 million in Q1 2025.